Evidence map›Paper›PMID 29022889›Full record

ArticleJournal of human hypertension2017

ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II).

S M C De Sousa, M Stowasser, J Feng, A W Schreiber, P Wang, C N Hahn, R D Gordon, D J Torpy, H S Scott, L Gagliardi

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Journal of human hypertension, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Molecular mechanisms ofCurrent opinion in endocrine and metabolic research · 2019
    Article
  3. Genetic Testing in Endocrinology.The Clinical biochemist. Reviews · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

S M C De SousaEndocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
M StowasserEndocrine Hypertension Research Centre, University of Queensland School of Medicine, Greenslopes and Princess Alexandria Hospitals, Brisbane, Australia.
J FengACRF Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, Australia.
A W SchreiberACRF Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, Australia.
P WangACRF Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, Australia.
C N HahnSchool of Medicine, University of Adelaide, Adelaide, Australia.
R D GordonEndocrine Hypertension Research Centre, University of Queensland School of Medicine, Greenslopes and Princess Alexandria Hospitals, Brisbane, Australia.
D J TorpyEndocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
H S ScottSchool of Medicine, University of Adelaide, Adelaide, Australia.
L GagliardiEndocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Germ-Line MutationAdultAgedArmadillo Domain ProteinsDNA Mutational AnalysisExome SequencingFemaleGenetic Predisposition to DiseaseHeredityHumansHyperaldosteronismMaleMiddle AgedPedigreePhenotypeRisk FactorsArmadillo Domain ProteinsARMC5 protein, humanTumor Suppressor Proteins

Identifiers

PMID29022889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.